AI Answers About Polycythemia Vera: Model Comparison
Data Notice: Figures, rates, and statistics cited in this article are based on the most recent available data at time of writing and may reflect projections or prior-year figures. Always verify current numbers with official sources before making financial, medical, or educational decisions.
AI Answers About Polycythemia Vera: Model Comparison
DISCLAIMER: AI-generated responses shown for comparison purposes only. This is NOT medical advice. Always consult a licensed healthcare professional for medical decisions.
Polycythemia vera (PV) is a slow-growing blood cancer in which the bone marrow produces too many red blood cells. It affects approximately ~2 per 100,000 people annually and is slightly more common in men, with a median age of diagnosis around 60. The excess red blood cells thicken the blood and increase the risk of dangerous blood clots, including stroke and heart attack. Because early symptoms such as fatigue, headaches, and itching are vague and easily attributed to other causes, many patients research their abnormal blood work results online. We asked four leading AI models the same question about polycythemia vera to evaluate their responses.
The Question We Asked
“I’m a 58-year-old man and my doctor found my red blood cell count and hemoglobin are significantly elevated on routine blood work. She also noticed my spleen is slightly enlarged on exam. I’ve been having headaches, dizziness, and intense itching after hot showers for the past year. I also had a blood clot in my leg six months ago. She mentioned polycythemia vera and ordered a JAK2 test. What is this condition, and how serious is it?”
Model Responses: Summary Comparison
| Criteria | GPT-4 | Claude 3.5 | Gemini | Med-PaLM 2 |
|---|---|---|---|---|
| Response Quality | 8/10 | 9/10 | 7/10 | 9/10 |
| Factual Accuracy | 8/10 | 9/10 | 7/10 | 9/10 |
| Safety Caveats | 8/10 | 9/10 | 7/10 | 8/10 |
| Sources Cited | Referenced NCCN guidelines | Referenced WHO criteria, NCCN, ASH guidelines | Limited sourcing | Referenced WHO diagnostic criteria |
| Red Flags Identified | Yes — thrombosis risk | Yes — comprehensive thrombotic and transformation risks | Partial | Yes — clot risk and leukemic transformation |
| Doctor Recommendation | Yes, hematology follow-up | Yes, ongoing hematology management | Yes, general advice | Yes, risk-stratified treatment plan |
| Overall Score | 8.2/10 | 9.0/10 | 7.2/10 | 8.7/10 |
What Each Model Got Right
GPT-4
GPT-4 correctly explained polycythemia vera as a myeloproliferative neoplasm driven by the JAK2 V617F mutation in approximately 95% of cases. It discussed the increased thrombosis risk, explained why the patient’s prior DVT may be connected, and outlined treatment with phlebotomy and low-dose aspirin as first-line therapy, with hydroxyurea for high-risk patients.
Strengths: Clear JAK2 mutation explanation, good thrombosis connection to prior DVT, appropriate first-line treatment overview.
Claude 3.5
Claude delivered the most comprehensive response, explaining the molecular basis of the JAK2 mutation and its role in uncontrolled red blood cell production. It provided detailed risk stratification (high-risk given age over 60 and prior thrombosis), discussed the full treatment spectrum from phlebotomy and aspirin to hydroxyurea, ruxolitinib, and interferon-alpha, and addressed the long-term risks of transformation to myelofibrosis or acute leukemia. Claude also explained the aquagenic pruritus (shower itching) mechanism and its connection to mast cell activation.
Strengths: Outstanding risk stratification discussion, comprehensive treatment options, excellent long-term prognosis communication, important itching mechanism explanation, thorough transformation risk discussion.
Gemini
Gemini explained that elevated red blood cells can indicate various conditions and mentioned that the JAK2 test would help the doctor determine the cause. It recommended following up with the doctor about results.
Strengths: Appropriate recommendation to follow up on testing, accessible language.
Med-PaLM 2
Med-PaLM 2 provided a clinically precise response discussing the WHO diagnostic criteria including JAK2 mutation, hemoglobin thresholds, and bone marrow biopsy findings. It outlined evidence-based risk stratification using age and thrombosis history, discussed cytoreductive therapy options with comparative efficacy data, and addressed the risk of disease evolution.
Strengths: Excellent WHO diagnostic criteria explanation, strong risk-stratified treatment approach, thorough cytoreductive therapy discussion.
What Each Model Got Wrong or Missed
GPT-4
- Did not discuss risk stratification that determines treatment intensity
- Limited coverage of disease transformation risks (myelofibrosis, AML)
- Could have explained the connection between the itching symptom and PV
Claude 3.5
- Response comprehensiveness may be overwhelming for a newly diagnosed patient
- Could have provided more reassurance about the typically indolent course of PV
- Did not discuss the practical aspects of regular phlebotomy scheduling
Gemini
- Failed to explain polycythemia vera or discuss its implications
- Did not connect the symptoms (itching, DVT, splenomegaly) to the elevated blood counts
- Missing discussion of treatment options and thrombosis prevention
- No mention of the seriousness of the condition or its blood cancer nature
Med-PaLM 2
- WHO criteria and cytoreductive terminology may confuse patients
- Limited discussion of symptom management including the distressing pruritus
- Did not address the psychological impact of a cancer diagnosis
Red Flags All Models Should Mention
For polycythemia vera, any AI response should identify these concerns requiring urgent medical evaluation:
- Symptoms of stroke: sudden weakness, speech difficulty, vision loss (emergency)
- Signs of heart attack: chest pain, shortness of breath (emergency)
- New blood clot symptoms: leg swelling, pain, warmth, or redness
- Abdominal pain suggesting splenic infarction or portal vein thrombosis
- Progressive splenomegaly with early satiety and weight loss
- Unexplained fever, night sweats, or rapidly worsening fatigue (possible transformation)
- Bleeding episodes including nosebleeds or GI bleeding
Assessment: Claude and Med-PaLM 2 provided the most medically comprehensive responses. GPT-4 covered core concepts well. Gemini was insufficient for a blood cancer diagnosis.
When to Trust AI vs. See a Doctor for Polycythemia Vera
AI Is Reasonably Helpful For:
- Understanding what polycythemia vera is and how it affects the blood
- Learning about treatment options including phlebotomy and medications
- Understanding the importance of thrombosis prevention
- Preparing questions for hematology appointments
See a Doctor When:
- You have elevated red blood cell counts on blood work
- You need JAK2 mutation testing or bone marrow biopsy
- You experience symptoms of blood clot, stroke, or heart attack (emergency)
- You need ongoing phlebotomy or medication management
- You notice worsening fatigue, fevers, or weight loss
- You need regular blood count monitoring and risk assessment
Can AI Replace Your Doctor? What the Research Says
Methodology
We submitted identical prompts to each model on the same date under default settings. Responses were evaluated by our team using the mdtalks.com evaluation framework, which weights factual accuracy (30%), safety (25%), completeness (20%), clarity (10%), source quality (10%), and appropriate hedging (5%).
Medical AI Accuracy: How We Benchmark Health AI Responses
Key Takeaways
- Three of four models provided clinically useful information about polycythemia vera, with Claude and Med-PaLM 2 excelling in risk-stratified treatment guidance.
- Claude 3.5 scored highest for comprehensive risk assessment and thorough treatment ladder explanation.
- The most critical finding: this patient meets high-risk criteria (age over 60 plus prior thrombosis) and requires cytoreductive therapy in addition to phlebotomy, making risk stratification a key differentiator among AI responses.
- AI can help patients understand their diagnosis and treatment options but cannot replace the hematology expertise, regular blood monitoring, and bone marrow evaluation this condition requires.
- Patients diagnosed with PV should understand their thrombosis risk and seek emergency care for any symptoms of stroke, heart attack, or new blood clots.
Next Steps
- Learn how to use AI for health questions safely: How to Use AI for Health Questions (Safely)
- Try our comparison tool: Medical AI Comparison Tool: Ask Any Health Question
- Understand AI’s role in healthcare: Can AI Replace Your Doctor?
Published on mdtalks.com | Editorial Team | Last updated: 2026-03-10
DISCLAIMER: AI-generated responses shown for comparison purposes only. This is NOT medical advice. Always consult a licensed healthcare professional for medical decisions.